In Q3 CY2025, Hologic (NASDAQ:HOLX) reported revenue of $1.05 billion, exceeding analyst estimates by 1.5% with a 6.2% year-on-year growth. Non-GAAP profit was $1.13 per share, beating consensus by 2.7%. The company, known for 3D mammography technology, focuses on women’s health and wellness. While revenue growth has been tepid at 1.7% annually over the last five years, recent performance shows demand slowing, with constant currency sales remaining flat. Operating margin was 22.6% in Q3, stable from last year. EPS grew to $1.13, up from $1.01 in the same quarter last year, exceeding expectations by 2.7%.

Read more at Stock Story: Hologic (NASDAQ:HOLX) Exceeds Q3 Expectations